FAROPENEM

SynDRA canonical compound SYN0019950 — structure-anchored drug synonym record

Clinical phase	Launched
Mechanism of action	lactamase inhibitor
Indication	bronchitis \| pneumonia \| sinusitis \| skin infections \| urinary tract infections
Disease area	infectious disease \| otolaryngology \| pulmonary

All known targets

faropenem sodium hydrate
fropenem
faropenem sodium
Fropenem
FPM
(+)-(5R,6S)-6-((1R)-1-Hydroxyethyl)-7-oxo-3-((2R)-tetrahydro-2-furyl)-4-thia-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid
(5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[(2R)-oxolan-2-yl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
(5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[(2R)-tetrahydrofuran-2-yl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
6alpha-[(1R)-1-hydroxyethyl]-2-[(2R)-tetrahydrofuran-2-yl]-2,3-didehydropenam-3-carboxylic acid
F52Y83BGH3
CHEBI:51257
DTXCID8026430
CHEBI:51788
faropenemum
RefChem:139969
J01DI03
faropenem medoxil\nfaropenem medoxil
NCGC00164546-02
Fropenem [INN]
CAS-106560-14-9
Faropenem [USAN:INN]
UNII-F52Y83BGH3
NCGC00164546-01
FAROPENEM [INN]
FAROPENEM [MI]
FAROPENEM [WHO-DD]
SCHEMBL239381
GTPL10808
HGGAKXAHAYOLDJ-FHZUQPTBSA-N
HY-A0035
Tox21_112175
BDBM50483324
compound 1 [PMID: 9216830]
AKOS015895072
Tox21_112175_1
EBC-616439
CS-0006739
NS00069663